MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
7.17
-0.64
-8.19%
After Hours: 7.25 +0.08 +1.12% 18:48 03/28 EDT
OPEN
8.00
PREV CLOSE
7.81
HIGH
8.26
LOW
7.03
VOLUME
4.06M
TURNOVER
0
52 WEEK HIGH
8.40
52 WEEK LOW
1.570
MARKET CAP
645.48M
P/E (TTM)
-4.0419
1D
5D
1M
3M
1Y
5Y
Annexon Is Maintained at Buy by B of A Securities
Dow Jones · 20h ago
Annexon Price Target Raised to $10.00/Share From $7.00 by B of A Securities
Dow Jones · 20h ago
B of A Securities Maintains Buy on Annexon, Raises Price Target to $10
Benzinga · 20h ago
Anticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data Readouts
TipRanks · 1d ago
Annexon Shares Rise 18% After 4Q Results Beat Estimates
Annexon shares rise 18% to $8.13 after fourth-quarter results topped analysts' expectations. The biopharmaceutical company reported a loss per share of 36 cents. Wells Fargo raised its price target on Annexon shares to $12 each from $11. The shares of Annexon hit a 52-week high of $9.40.
Dow Jones · 1d ago
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Shares of Cintas Corporation jumped 9.7% to $694.62 on Wednesday. The company reported better-than-expected third-quarter financial results and raised FY24 guidance. PaySign, Inc. Shares jumped 28.2% after the company announced better- than-expected fourth-quarter results. Dow Jones index gained around 300 points in Wednesday's session.
Benzinga · 2d ago
Annexon Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
Annexon Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is also evaluating ANX005 for the potential treatment of patients with Huntington’s disease (HD). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.